Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21230106 | 0.86 | MBOAT4 (0.57) | MBOAT4 | |
| SCHEMBL21230058 | 0.85 | MBOAT4 (0.56) | MBOAT4 | |
| SCHEMBL21230059 | 0.83 | MBOAT4 (0.60) | MBOAT4 | |
| SCHEMBL21223048 | 0.80 | MBOAT4 (0.61) | MBOAT4 | |
| SCHEMBL21230097 | 0.79 | MBOAT4 (0.74) | MBOAT4 | |
| SCHEMBL21230102 | 0.78 | MBOAT4 (0.64) | MBOAT4 | |
| SCHEMBL21222820 | 0.77 | MBOAT4 (0.57) | MBOAT4 | |
| SCHEMBL21230099 | 0.77 | MBOAT4 (0.62) | MBOAT4 | |
| SCHEMBL21230088 | 0.77 | MBOAT4 (0.61) | MBOAT4 | |
| Hydrochloric Acid SCHEMBL21222969 | 0.76 | MBOAT4 (0.60) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319310-B2 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3746450-B1 | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210040077-A1 | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2021-02-11 | — | — | US | disclosed |
| WO-2019149659-A1 | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319310-B2 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, NPY1R, GIPR | MBOAT4 1/4885 |
| US-20210040077-A1 | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | MBOAT4, NPY1R, GIPR | MBOAT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.